DGAP-News: VENITI, Inc. Announces First Uses of Veniti Vici Venous Stent System

        Print
| Source: EQS Group AG
DGAP-News: VENITI, Inc. /
VENITI, Inc. Announces First Uses of Veniti Vici Venous Stent System

23.01.2014 / 23:19

---------------------------------------------------------------------

Live Case Demonstration Scheduled for Leipzig Interventional Course (LINC)

ST. LOUIS, 2014-01-23 23:19 CET (GLOBE NEWSWIRE) --
VENITI announced today that patients in the European Union (EU) were
successfully treated for symptomatic venous outflow obstruction of the lower
extremities with the Veniti Vici(tm) Venous Stent System. These procedures mark
the first uses in patients of this novel Venous Stent from VENITI. 

More procedures using the Veniti Vici Venous Stent System are scheduled at
various locations in the EU, including a live case demonstration at the Leipzig
Interventional Course (LINC) on 28 January 2014. 

The Veniti Vici Venous Stent was designed from inception to be compatible with
the unique anatomy and pathology of the venous system to specifically address
the unmet need for a dedicated venous stent. Hundreds of thousands of people
around the world suffer from lower-extremity venous disease, and until
recently, the only treatment options available involved the use of re-purposed
vascular stents originally designed for use in the arterial system, which
physicians know is vastly different from the venous system in terms of
hemodynamics, physiology, pathophysiology and other important characteristics. 

Mr. Stephen Black, a Consultant Vascular Surgeon at the prestigious St.
George's Vascular Institute, St. George's Hospital, London, implanted Veniti
Vici Stents in five patients on 14 and 15 January. 'The Veniti Vici Venous
Stent appears to have the radial strength and vein coverage to provide optimal
results in patients with symptomatic outflow obstruction of the lower
extremities,' said Mr. Black. 'Having a stent that was designed from its
inception for use in veins makes this an important addition to my treatment
options.' 

Dr. Peter Neglen, a noted pioneer in venous stenting, who was also present at
St Georges on 14 and 15 January commented: 'The Veniti Vici Stent placement
today in patients represented the culmination of years of working with venous
stent designs to better suit the unique characteristics of the venous anatomy
and venous disease.' 

Dr. Gerard O'Sullivan at the prominent Galway University Hospitals, Galway,
Ireland who implanted the Veniti Vici stent on 16 January also commented that
'The Veniti Vici Venous Stent is a step forward in venous stenting to help
treat patients suffering from venous outflow obstruction.' 

'We are pleased that the unique advantages of a stent designed specifically for
the venous system--including end-to-end crush resistance, higher radial
resistive force, flexibility, and continuous vein coverage--are available to
physicians treating venous outflow obstructions in the lower extremities,'
noted Scott Solano, VENITI President and Chief Executive Officer. 'We believe
the Veniti Vici Stent offers significant patient benefit due to its
venous-specific design.' 

Mr. Solano and Daniel Krelle, VENITI European Marketing Director, will attend
LINC 28-31 January and will be available to meet attendees and the media at the
VENITI booth (Number 37). 

About VENITI, Inc.

VENITI is a leading provider of innovative medical devices singularly focused
on venous care. With three product lines: The Veniti Vici(tm) Venous Stent
System, 
the Veniti Veni(tm) RF Plus Ablation System, and the Veniti Vidi(tm) Inferior
Vena 
Cava (IVC) Filter System, VENITI is offering significant benefit to patients
who suffer from lower extremity venous outflow obstruction or varicose veins,
as well as those at risk of pulmonary embolism. 

The Veniti Vici(tm) Venous Stent System is CE Marked under the European Medical
Device Directive (MDD) 93/42/EEC, and VENITI is seeking approval from the U.S.
Food and Drug Administration (FDA) to begin clinical studies of the device in
the United States. The Veniti Veni(tm) RF Plus Endovascular Ablation System is
also CE Marked under the European Medical Device Directive (MDD) 93/42/EEC. The
Veniti Vidi(tm) IVC Filter System is in early stages of clinical studies in New
Zealand, and VENITI is seeking approval from the US FDA to begin clinical
studies of the device in the United States. VENITI Headquarters is located in
St. Louis, Missouri, USA while its Research & Development and Manufacturing
divisions are located in Fremont, California, USA. For more information, call
+1 314 282 3753 or visit www.veniti.com. 

Company Contact:
Scott Solano
+1 (314) 338 3019

The Veniti Vici Venous Stent System is CE Marked under the European Medical
Device Directive (93/42/EEC); it is not available for sale in the United
States. VENITI, the VENITI logo, and VENITI VICI are trademarks of VENITI, Inc. 


         Media Contact: Daniel Krelle
         +44 7562 600 555
         dkrelle@veniti.com
News Source: NASDAQ OMX


End of Corporate News

---------------------------------------------------------------------

23.01.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language:    English        
Company:     VENITI, Inc.   
 
 
             United States  
 
 
End of News    DGAP News-Service  
---------------------------------------------------------------------  
249389 23.01.2014